PharmaTalkRadio

Subcutaneous (SC) delivery has become the norm for treating diseases such as Rheumatoid arthritis and multiple sclerosis, and there remains great potential to offer home- or even self-administered SC delivery for several other biotherapeutics. Given that there are a number of products already on the market, they can be examined to understand what improvements and changes can be made to increase product development opportunities and also enhance the patient experience.

In this podcast, first recorded at the 2019 PODD: Partnership Opportunities in Drug Delivery conference, you will hear from clinicians (pharmacist and physician) and industry to gain insight into needs and preferences of future SC biotherapeutic formulations and devices. For example, panelists will address the issue of reducing costs and dose complexity, improving adherence, and also provide input on changes they would like to see in future SC biotherapeutic products.

Moderated by: Dr Beate Bittner, Roche

Panelists include:

Dr Mary Nauffal, Brigham and Women's HospitalDr Manuel Sanchez-Felix, Novartis Institutes for BioMedical ResearchDr Anand Subramony, AstraZenecaDr David Ting, MGH Cancer Center/Harvard Medical School

To learn more about the 10th annual PODD: Partnership Opportunities in Drug Delivery conference please visit www.theconferenceforum.org

This podcast, first recorded at the 2019 PODD: Partnership Opportunities in Drug Delivery conference explores the value of drug delivery technologies both to patients and pharma with a focus on the future direction of the field. This will include a review of the state of the art for traditional modalities such as small molecules and biologics and then expand the conversation to the challenges for less common modalities such as peptides and nucleic acids. The panel members will discuss the potential scientific barriers for these future delivery technologies and the industry's willingness to invest to address these barriers.

Moderated by: Dr Shawn Davis, AstraZeneca

Panelists include:

Dr Advait Badkar, PfizerAndré LaFreniere, BattelleMaria Teresa Peracchia, SanofiDr Julia Rashba-Step, PhosphorexTheresa Scheuble, Johnson & Johnson

To learn more about the 10th annual PODD: Partnership Opportunities in Drug Delivery conference please visit www.theconferenceforum.org

Merck has a long history of being open to utilizing a wide range of delivery technologies for both enabling and life cycle management. In this leadership keynote, first recorded at the 2019 PODD: Partnership Opportunities in Drug Delivery conference, Dr Allen Templeton, VP, Pharmaceutical Sciences, discusses how Merck's strategy of utilizing DDS has evolved and the role of enabling drug delivery technologies play in the Merck R&D pipeline. What emerging DDS technologies and modalities does Merck view as the most promising, and why.

To learn more about the upcoming 10th annual PODD: Partnership Opportunities in Drug Delivery conference please visit, www.theconferenceforum.org

In this podcast, first recorded at the 2019 PODD: Partnership Opportunities in Drug Delivery conference, John Merhige, Credence MedSystems, Inc and Mathias Romacker, formly with Pfizer discuss the journey of an emerging medical device company from a blank piece of paper toward commercialization.

Topics include:

The early days: starting the company and inventing with implementation in mindThe importance of listening to the customer and incorporating feedback early - and why that can be difficultStaying in the long game - the mindset, endurance and approach to ensure you are ready when opportunity appearsCollaborating within the supply chain - why it's challenging and the right approach

To learn more about the 10th annual PODD: Partnership Opportunities in Drug Delivery conference please visit www.theconferenceforum.org

Effective drug delivery collaborations combine a wide range of experiences and viewpoints with common goals to achieve successful clinical and regulatory outcomes. But the path to developing this eventual relationship is not without challenges, as partnerships that are not clearly defined upfront or effectively managed downstream can quickly derail the best of intentions. In this podcast, first recorded at the 2019 PODD: Partnership Opportunities in Drug Delivery conference, BMS and Halozyme panelists will shed light on key considerations, challenges and lessons learned during the pre-deal courting process as well as their ongoing successful alliance.

Moderated by: Jennifer Guzman, Halozyme Therapeutics

Panelists include:

Michael Cucolo, BMSBrian Davideit, BMSRenee Tannenbaum, Halozyme TherapeuticsTom Witt, Halozyme Therapeutics

To learn more about the 10th annual PODD: Partnership Opportunities in Drug Delivery conference please visit www.theconferenceforum.org

How are industry leaders looking to bridge the gap from pilot systems to scaled solutions in the market? In this podcast, first recorded at the 2019 PODD: Partnership Opportunities in Drug Delivery conference, a panel of Connected Health leaders in the industry provide their views on how they are developing value propositions that resonate with internal and external stakeholders. Defining business and operational models that benefit patients and support evolving healthcare payment structures, while delivering strong returns to the business is central to this discussion.

Moderated by: Kevin Deane, Phillips-Medisize Company

Panelists include:

Dhairya Mehta, TakedaPaul Upham, Roche/GenentechPaul Schultz, BrightInsightAmir Zur, Teva Pharmaceuticals

To learn more about the 10th annual PODD: Partnership Opportunities in Drug Delivery conference please visit www.theconferenceforum.org

Given the increase in focus on digital health and connected device development to improve "patient centricity" and the user experience, there is a large amount of clarity and evidence needed on how to truly ladder in these efforts to achieve the uiltimate outcome for patients. The answer lies in leveraging the power of contextualized, extrinsic data that while readily available given the acceleration of technologies and tools available today, are not readily apparent to connected therapeutic ecosystems as a whole - patients, clinicians, and developers of products and solutions.

This podcast, first recorded at the 2019 PODD: Partnership Opportunities in Drug Delivery conference, Dr Chris Kovalchick, Eli Lilly and Company, discusses examples from both inside and outside the drug delivery industry to demonstrate how interrogating the massive amount of environmental and background information readily available can be used to activate the seismic shift needed to move us all towars the ultimate goal for all of our customers - improved wellness and awareness.

To learn more about the 10th annual PODD: Partnership Opportunities in Drug Delivery conference please visit www.theconferenceforum.org

In the fourth episode of our series highlighting rare diseases, Conference Forum reporter Danny McCarthy sits down with Neena Nizar, EdD, Founder and Executive Director of the Jansen's Foundation, to discuss Jansen's Metaphyseal Chondrodysplasia. 

Jansen type metaphyseal chondrodysplasia is an extremely rare progressive disorder in which portions of the bones of the arms and legs develop abnormally with unusual cartilage formations and subsequent abnormal bone formation. 

The Jansen's Foundation goal is to speed up and fund the process of finding a cure and treatment for the rare disease. For more information:

https://www.thejansensfoundation.org/

For more information about our podcasts and the upcoming Patients as Partners event:

www.theconferenceforum.org

In this podcast, first presented at the 9th annual DPharm: Disruptive Innovations conference, Cellarity's Milind Kamkolkar presents on the collective struggle to evolve a drug development organization's data and analytics culture and capabilities. Including:

The theory of going digital in drug developmentIdentifying hype from realityWhat is the program we are trying to solve?Take a big, complex organization and evolving it to be digitally modernWhat is the intended use of the data?Priorities, structure, culture and next steps

Speaker: Milind Kamkolkar, Chief Data Officer, Cellarity

The 10th annual DPharm: Disruptive Innovations event is scheduled to take place on September 22-23, 2020. Learn more here.

In this podcast, first presented at the 9th annual DPharm: Disruptive Innovations conference, Genentech's Aaron Mann discusses the use of historical data to transform clinical trials and how to rethink clinical development.

Speaker: Aaron Mann, Global Program Lead, Industry Collaborations Data Sharing Initiatives, Genentech, a member of the Roche Group

The 10th annual DPharm: Disruptive Innovation event is scheduled to take place on September 22-23, 2020. Learn more here.